HM Capital Management LLC Makes New Investment in Allergan plc (NYSE:AGN)

HM Capital Management LLC acquired a new position in shares of Allergan plc (NYSE:AGN) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 4,552 shares of the company’s stock, valued at approximately $762,000. Allergan comprises 0.5% of HM Capital Management LLC’s holdings, making the stock its 23rd biggest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in AGN. FMR LLC boosted its position in Allergan by 42.0% during the 1st quarter. FMR LLC now owns 6,042,005 shares of the company’s stock worth $884,611,000 after acquiring an additional 1,788,265 shares during the period. Janus Henderson Group PLC boosted its position in Allergan by 27.6% during the 1st quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock worth $857,312,000 after acquiring an additional 1,265,742 shares during the period. Ellis Investment Partners LLC raised its stake in shares of Allergan by 14,302.8% during the 1st quarter. Ellis Investment Partners LLC now owns 852,214 shares of the company’s stock worth $852,000 after purchasing an additional 846,297 shares in the last quarter. Clearbridge Investments LLC raised its stake in shares of Allergan by 8.6% during the 1st quarter. Clearbridge Investments LLC now owns 9,167,006 shares of the company’s stock worth $1,342,141,000 after purchasing an additional 726,688 shares in the last quarter. Finally, Artisan Partners Limited Partnership raised its stake in shares of Allergan by 6.5% during the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock worth $990,867,000 after purchasing an additional 410,746 shares in the last quarter. Hedge funds and other institutional investors own 80.06% of the company’s stock.

Shares of AGN stock opened at $161.02 on Friday. The firm has a 50 day moving average of $155.74. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.71 and a quick ratio of 0.60. Allergan plc has a twelve month low of $114.27 and a twelve month high of $197.00. The company has a market cap of $52.75 billion, a P/E ratio of 9.65, a price-to-earnings-growth ratio of 1.51 and a beta of 1.63.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $3.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.55 by $0.24. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The business had revenue of $3.60 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same period last year, the business earned $3.74 EPS. The firm’s revenue was down 2.0% compared to the same quarter last year. Sell-side analysts predict that Allergan plc will post 16.77 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 13th will be paid a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.84%. The ex-dividend date of this dividend is Monday, August 12th. Allergan’s payout ratio is 17.74%.

A number of equities research analysts have recently weighed in on AGN shares. JPMorgan Chase & Co. set a $200.00 price target on Allergan and gave the stock a “buy” rating in a research note on Wednesday, June 19th. Sanford C. Bernstein downgraded Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price target for the company. in a research note on Tuesday, July 16th. Goldman Sachs Group started coverage on Allergan in a research note on Tuesday, May 28th. They set a “neutral” rating and a $154.00 price target for the company. UBS Group cut their price target on Allergan from $173.00 to $172.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Finally, Mizuho downgraded Allergan from a “buy” rating to a “neutral” rating and raised their price target for the stock from $171.00 to $188.00 in a research note on Wednesday, June 26th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have assigned a buy rating to the company. Allergan currently has a consensus rating of “Hold” and a consensus target price of $175.48.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Featured Story: What is the Quick Ratio?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.